Article
Biochemistry & Molecular Biology
C. R. Simpson, T. Shi, E. Vasileiou, S. V. Katikireddi, S. Kerr, E. Moore, C. McCowan, U. Agrawal, S. A. Shah, L. D. Ritchie, J. Murray, J. Pan, D. T. Bradley, S. J. Stock, R. Wood, A. Chuter, J. Beggs, H. R. Stagg, M. Joy, R. S. M. Tsang, S. de Lusignan, R. Hobbs, R. A. Lyons, F. Torabi, S. Bedston, M. O'Leary, A. Akbari, J. McMenamin, C. Robertson, A. Sheikh
Summary: Analysis of data from the EAVE II cohort in Scotland has shown that a first dose of the ChAdOx1 nCoV-19 vaccine may be associated with increased risks of idiopathic thrombocytopenic purpura, arterial thromboembolic events, and hemorrhagic events. However, there were no positive associations found between the BNT162b2 vaccine and these adverse events.
Article
Medicine, General & Internal
Vanessa Alexandra Buetler, Nada Agbariah, Deborah Pia Schild, Fabian D. Liechti, Anna Wieland, Nicola Andina, Felix Hammann, Johanna A. Kremer Hovinga
Summary: This article presents a case of iTTP following COVID-19 vaccination and reviews previously reported cases. The findings suggest a potential association between COVID-19 vaccination and iTTP.
FRONTIERS IN MEDICINE
(2022)
Review
Hematology
Prachi Saluja, Nitesh Gautam, Sisira Yadala, Anand N. Venkata
Summary: With the advent of COVID-19 vaccines, there have been reports of autoimmune hematological complications such as TTP occurring after vaccination. This study reviewed existing cases of TTP after COVID-19 vaccination and found that it is more common after BNT162b2 and mRNA-1273 vaccines. Treatment for immune TTP typically involves plasma exchange and steroids. An in-depth anamnesis before vaccination is important, and the possibility of TTP should be considered when evaluating post-vaccine thrombocytopenia.
THROMBOSIS RESEARCH
(2022)
Article
Clinical Neurology
Peter Tatum
Summary: This report describes a case of a 56-year-old male who developed unilateral right thigh numbness after receiving his second Moderna COVID-19 vaccine. A raised, painless area with a red border appeared in the center of the thigh after one week and resolved spontaneously after 2 weeks. This is the first documented case of meralgia paresthetica following COVID-19 vaccination without any other risk factors. COVID vaccines may be a potential cause of localized peripheral neuropathy.
NEUROLOGICAL SCIENCES
(2023)
Review
Immunology
Imen Ben Saida, Iyed Maatouk, Radhouane Toumi, Emna Bouslama, Hajer Ben Ismail, Chaker Ben Salem, Mohamed Boussarsar
Summary: This is the first report of acquired TTP after inactivated virus COVID-19 vaccination, and the patients recovered after treatment with corticosteroids, plasma exchange therapy, and rituximab.
Article
Emergency Medicine
Kah-Meng Chong, Ching-Yao Yang, Chien-Chin Lin, Wan-Ching Lien
Summary: We report a rare case of severe immune thrombocytopenia in an Asian woman following the administration of the Moderna COVID-19 vaccine. This highlights a potential adverse effect of mRNA-based vaccines in cancer patients receiving immune checkpoint inhibitors.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2022)
Article
Medicine, General & Internal
Vrushali Saudagar, Satish Patil, Shaun Goh, Sohil Pothiawala
Summary: Patients with immune thrombocytopenic purpura (ITP) are at an increased risk of developing the condition after receiving certain vaccines, especially with the widespread vaccination drives for COVID-19 in recent years. Although the exact pathogenesis remains unclear, there have been few reported cases of vaccine-induced thrombocytopenia in pharmacovigilance databases.
IRISH JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Immunology
Vladimir Atanasov, Natalia Barreto, Jeff Whittle, John Meurer, Benjamin W. W. Weston, Qian Eric Luo, Andy Ye Yuan, Lorenzo Franchi, Ruohao Zhang, Bernard Black
Summary: Prior research shows that Pfizer and Moderna COVID-19 vaccines offer similar protection against mortality, with Pfizer having a slight advantage. However, most comparisons did not consider the selection effects of vaccine recipients. This study provides evidence of large selection effects and introduces a novel method to control for these effects. The results show that Pfizer has a higher relative mortality risk compared to Moderna for individuals aged 60 and above, but the difference is smaller and not statistically significant for booster recipients. The study also suggests the possibility of a higher vaccine dose for older individuals.
Article
Medicine, General & Internal
Srikrishna Malayala, Gisha Mohan, Deepa Vasireddy, Paavani Atluri
Summary: This case report describes a 60-year-old male patient who developed purpuric rash and thrombocytopenia after receiving the mRNA-1273 vaccine. He had underlying health issues such as smoking history, liver cirrhosis, chronic kidney disease, hypertension, and heart failure. The symptoms are believed to be side effects of the vaccine based on limited literature and the absence of other underlying causes.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Review
Immunology
Prachi Saluja, F. N. U. Amisha, Nitesh Gautam, Harmeen Goraya
Summary: A systematic review on patients with immune thrombocytopenia (ITP) after COVID-19 vaccination revealed a higher association with mRNA vaccines and promising outcomes without reported deaths.
Article
Hematology
Severine de Bruijn, Marie-Berthe Maes, Laure De Waele, Karen Vanhoorelbeke, Alain Gadisseur
Summary: This case report describes a 38-year-old woman who developed de novo iTTP after receiving an mRNA-based COVID-19 vaccine. She presented with skin bruising and petechiae 2 weeks after vaccination. Treatment with plasma exchange, corticosteroids, rituximab, and caplacizumab was successful in managing her condition.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Cardiac & Cardiovascular Systems
Gaurav Dhingra, Manideepa Maji, Saikat Mandal, Sudeep Vaniyath, Gita Negi, Uttam Kumar Nath
Summary: Thrombotic thrombocytopenic purpura (TTP), a rare but dangerous vascular disease, often requires therapeutic plasma exchange to maintain platelet count. COVID-19 infection can also trigger TTP, requiring further research into effective management strategies for this condition.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2021)
Review
Hematology
Ali Bidari, Sara Asgarian, Arash Pour Mohammad, Delaram Naderi, Shiva Rahimipour Anaraki, Milad Gholizadeh Mesgarha, Mahya Naderkhani
Summary: This systematic review aimed to analyze the epidemiological characteristics, clinical course, therapeutic strategies, and outcome of patients diagnosed with de novo immune thrombocytopenic purpura (ITP) after COVID-19 immunization. A total of 77 patients were identified, with most cases being associated with mRNA-based and adenovirus vector-based COVID-19 vaccines. The majority of patients responded well to treatment.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Srikrishna Malayala, Bhavani N. Papudesi, Rishika Sharma, Urwat T. Vusqa, Ambreen Raza
Summary: Vaccination is crucial in reducing morbidity and mortality from the Covid-19 pandemic, with most vaccines being considered safe. A case report highlighted a patient who developed VITT after receiving a booster dose, but no such cases have been reported after the third dose of the Pfizer-Biontech vaccine so far.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Dermatology
Margaret S. Johnston, Anjela Galan, Kalman L. Watsky, Alicia J. Little
Summary: In response to the COVID-19 pandemic, mRNA vaccines from Pfizer-BioNTech and Moderna received emergency use authorization in the US. This study focused on localized cutaneous reactions to the Moderna COVID-19 vaccine, finding them to be delayed hypersensitivity reactions that are self-limited and not associated with serious adverse effects. Most patients who had a reaction to the first vaccine dose also developed a similar reaction to the second dose, typically sooner. The reactions, dubbed COVID arm, are not a contraindication to subsequent vaccination.
